Autolus Therapeutics (NASDAQ:AUTL) Trading Down 10.1% – What’s Next?

Shares of Autolus Therapeutics plc (NASDAQ:AUTL) fell 10.1% during trading on Friday . The stock traded as low as $3.63 and last traded at $3.63. 1,146,264 shares changed hands during trading, a decline of 18% from the average session volume of 1,391,843 shares. The stock had previously closed at $4.04.

Autolus Therapeutics Price Performance

The stock has a market capitalization of $992.52 million, a PE ratio of -3.22 and a beta of 2.04. The firm’s 50 day simple moving average is $3.99 and its 200 day simple moving average is $4.01. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.55 and a quick ratio of 18.55.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). As a group, equities analysts forecast that Autolus Therapeutics plc will post -0.84 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. ProShare Advisors LLC purchased a new position in shares of Autolus Therapeutics in the second quarter worth $43,000. Daiwa Securities Group Inc. increased its stake in shares of Autolus Therapeutics by 2,659.7% in the second quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock worth $55,000 after buying an additional 15,293 shares during the period. Herbst Group LLC purchased a new position in shares of Autolus Therapeutics in the third quarter worth $91,000. Bayesian Capital Management LP purchased a new position in Autolus Therapeutics during the 1st quarter valued at $100,000. Finally, B. Riley Wealth Advisors Inc. purchased a new position in Autolus Therapeutics during the 1st quarter valued at $108,000. 72.83% of the stock is owned by hedge funds and other institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.